[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344746-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344746-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","irf7-is-a-novel-prognostic-biomarker-in-kidney-renal-clear-cell-carcinoma","IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma","","IRF7 is an interferon regulatory factor whose prognostic function in kidney renal clear cell carcinoma (KIRC) was assessed using multi-omics resources including TCGA, GTEx, CPTAC, and tissue microarrays. Survival outcomes (DSS/PFI/OS), functional enrichment (GSEA), drug sensitivity (GSCA), single-cell functional states (CancerSEA), and a KIRC-specific prognostic nomogram were integrated. IRF7 was dysregulated across 22 cancers and elevated IRF7 expression associated with worse survival in KIRC, linked to immune checkpoint and methylation features. Functional analyses implicated fatty acid metabolism, oxidative phosphorylation, and therapy response, with microarrays confirming overexpression and reduced survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/irf7-is-a-novel-prognostic-biomarker-in-kidney-renal-clear-cell-carcinoma/344746/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/irf7-is-a-novel-prognostic-biomarker-in-kidney-renal-clear-cell-carcinoma/344746.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study on IRF7 in KIRC?","Question",{"text":63,"@type":64},"To determine whether IRF7 can serve as a prognostic biomarker in kidney renal clear cell carcinoma and to clarify its links to tumor immunity and therapy response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and analyses were used to evaluate IRF7?",{"text":68,"@type":64},"The study integrated TCGA, GTEx, CPTAC, and tissue microarrays, analyzing survival outcomes, functional enrichment, drug sensitivity, single-cell functional states, and building a prognostic nomogram.",{"name":70,"@type":61,"acceptedAnswer":71},"How did IRF7 expression relate to patient outcomes in KIRC?",{"text":72,"@type":64},"Elevated IRF7 expression correlated with poorer survival in KIRC, and tissue microarrays confirmed IRF7 overexpression in tumor versus normal tissues.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344746,1790316642,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma  \nShuangshuang Fu1, Wenhui Zhou1, Wei Yin1, Ying Chen1, Liyuan Cao1, Yusa Chen1,2􀀍 & Zheng Xiao1,2􀀍  \nInterferon regulatory factor 7 (IRF7) regulates immune responses but its prognostic role in kidney renal clear cell carcinoma (KIRC) is undefined. Given KIRC’s high incidence (70–80% of renal cancers) and limited late-stage therapies, we assessed IRF7’s clinical utility through multi-omics analysis. Using TCGA, GTEx, CPTAC, and tissue microarrays, we analyzed IRF7 in 33 cancers. Assessments included survival (DSS/PFI/OS), functional enrichment (GSEA), drug sensitivity (GSCA), single-cell functional state analysis using the CancerSEA database, and prognostic nomogram construction.  \nIRF7 was dysregulated in 22 cancers (KIRC: p\u003C 0.001), with elevated expression correlating to poor survival (p \u003C 0.01) . It associated with immune checkpoints, epigenetic modifiers, T-cell activity, and methylation. Functional analyses implicated IRF7 in fatty acid metabolism, oxidative phosphorylation, and drug sensitivity. A KIRC-specific nomogram predicted OS with high accuracy. Tissue microarrays confirmed IRF7 overexpression in KIRC versus normal tissues (p \u003C 0.001), linked to reduced survival. IRF7 is a novel prognostic biomarker in KIRC, influencing tumor immunity and therapy response. Its integration into clinical nomograms could guide precision immunotherapy strategies.  \nKeywords Interferon regulatory factor 7, Kidney renal clear cell carcinoma, Prognosis, Biomarker  \nPan-cancer comprises a variety of malignancies, with Kidney renal clear cell carcinoma (KIRC) being notably prominent due to its rising incidence and significant economic burden on healthcare systems. KIRC accounts for approximately 70–80% of all renal cancer cases, the estimated worldwide incidence rate is approximately 3.5 cases per 100,000 individuals according to the Global Cancer Observatory (GLOBOCAN) 2020 report1. Current diagnostic and treatment methods for KIRC primarily rely on imaging and surgical approaches, which are often ineffective in advanced stages2. The inconsistency of responses to targeted therapies and immunotherapies underscores the urgent need for reliable biomarkers to enhance diagnostic precision and prognostic assessment. The Interferon Regulatory Factor 7 (IRF7) serves as an essential transcription factor that modulates type I interferon responses, playing a significant role in the immune system’s defense mechanisms against viral infections3. Recent studies have revealed IRF7’s complex implications in various cancers, where it may promote anti-tumor immunity while also facilitating tumor progression in certain contexts4. Despite extensive research, the specific mechanisms governing IRF7’s expression and function across different cancer types remain insufficiently understood, indicating a gap in our knowledge of its clinical implications in a pan-cancer context.  \nAdditionally, although some research has indicated altered IRF7 expression in different malignancies, correlating its levels with patient outcomes, comprehensive analyses across diverse tumor types are lacking. This highlights the opportunity to explore IRF7’s potential as a diagnostic and prognostic biomarker, which could lead to more tailored therapeutic strategies. Our study aims to address these gaps by integrating bioinformatics analyses, survival curve evaluations, and drug sensitivity assessments, focusing on the expression data of IRF7 derived from pan-cancer cohorts obtained from TCGA.  \nThrough this multifaceted approach, we will investigate the clinical relevance of IRF7 concerning key oncogenic characteristics include microsatellite instability (MSI) and tumor mutation burden (TMB). Functional enrichment analyses will identify pathways and biological processes influenced by IRF7, while assessing cancer cell lines’ sensitivity ","cbCaib0lrGj97yuv","https://ap.wps.com/l/cbCaib0lrGj97yuv","pdf",8622874,14,"English","# Introduction\n## Study rationale and research gap\n## Study aims and approach\n# Materials and methods\n## RNA-Seq data and clinical feature sourcing\n## CPTAC and UALCAN","[{\"question\":\"What was the main goal of the study on IRF7 in KIRC?\",\"answer\":\"To determine whether IRF7 can serve as a prognostic biomarker in kidney renal clear cell carcinoma and to clarify its links to tumor immunity and therapy response.\"},{\"question\":\"Which datasets and analyses were used to evaluate IRF7?\",\"answer\":\"The study integrated TCGA, GTEx, CPTAC, and tissue microarrays, analyzing survival outcomes, functional enrichment, drug sensitivity, single-cell functional states, and building a prognostic nomogram.\"},{\"question\":\"How did IRF7 expression relate to patient outcomes in KIRC?\",\"answer\":\"Elevated IRF7 expression correlated with poorer survival in KIRC, and tissue microarrays confirmed IRF7 overexpression in tumor versus normal tissues.\"}]","IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma | PDF",1790055137,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d839a878e4c60db3da0333d9bd4ad37.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cfebcfbce3d8dd4ff07e839a7d5245c.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99225a3f3df308c453cbd5e084e0e60e.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1feba960766e5f564fa5751ac7dbee5.webp",980,1287]